IP Library Granted Patent US 10,029,030
Granted Patent B2
US 10,029,030 · App. 13/815,753 · Granted Jul 24, 2018

Molded placental tissue compositions and methods of making and using the same

Inventors: Thomas J. Koob (Kennesaw, GA); Guilhem Denoziere (Kennesaw, GA); Rebeccah J.C. Brown (Kennesaw, GA)
Assignee: MiMedx Group, Inc.
A61L27/3604A61L27/3695A61L2400/06A61L2430/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,029,030
App. No.
13/815,753
Granted
Jul 24, 2018
Kind
B2
Abstract

Described herein are molded dehydrated placental tissue compositions, and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the molded dehydrated placental tissue compositions are also described herein.

Claims (15)

1. A method for enhancing wound healing, the method comprising applying a placental tissue composition at or near the site of the wound; wherein said composition has a defined size and shape; wherein said composition comprises micronized amnion, and optionally one or more of micronized amnion, micronized chorion, micronized intermediate tissue layer, and any combination thereof; wherein at least one of the micronized amnion comprises a fibroblast cell layer; when said composition is molded and dehydrated; wherein said composition is not cross-linked and has a sufficient density and cohesiveness to maintain its size and shape for a defined period of time ex vivo and in vivo; and wherein the density is from 1.2 g/cm 3 to 10 g/cm 3 .

2. The method of claim 1 , wherein the composition is administered sub-cutaneously, sub-dermally, intramuscularly, or at the periosteal interface.

3. The method of claim 1 , wherein the composition is a pharmaceutical composition.

4. The method of claim 3 , said pharmaceutical composition further comprising a pharmaceutically acceptable excipient.

5. The method of claim 1 , wherein the water content of the composition is less than 15%.

6. The method of claim 1 , wherein the water content of the composition is less than 10%.

7. The method of claim 1 , wherein the water content of the composition is less than 5%.

8. The method of claim 1 , wherein the micronized amnion, micronized chorion, micronized intermediate tissue layer, or any combination thereof has a particle size of less than 350 μm.

9. The method of claim 1 , wherein the micronized amnion, micronized chorion, micronized intermediate tissue layer, or any combination thereof has a particle size of less than 300 μm.

10. The method of claim 1 , wherein the water content of the composition is less than 20%.

11. The method of claim 1 , wherein the micronized amnion, micronized chorion, micronized intermediate tissue layer, or any combination thereof has a particle size of less than 400 μm.

12. A method for enhancing wound healing, the method comprising applying a placental tissue composition at or near the site of the wound, wherein said composition has a defined size and shape; wherein said composition consists of micronized amnion wherein the micronized amnion comprises a fibroblast cell layer; wherein said composition is molded and dehydrated; and wherein said composition is not cross-linked and has a sufficient density and cohesiveness to maintain its size and shape for a defined period of time ex vivo and in vivo wherein the density is from 1.2 g/cm 3 to 10 g/cm 3 .

13. The method of claim 12 , wherein the composition is a pharmaceutical composition.

14. The method of claim 12 , wherein the water content of the composition is less than 20%, less than 15%, less than 10%, or less than 5%.

15. The method of claim 12 , wherein the micronized amnion has a particle size of less than 400 um, less than 350 um, or less than 300 um.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Feb 5, 2024
From: HAYFIN SERVICES LLP
To: MIMEDX GROUP, INC.; MIMEDX PROCESSING SERVICES, LLC
Reel/Frame 066493/0322 →
SECURITY INTEREST Recorded Jan 25, 2024
From: MIMEDX GROUP, INC.
To: CITIZENS BANK, N.A.
Reel/Frame 066371/0136 →
PATENT SECURITY AGREEMENT Recorded Jul 2, 2020
From: MIMEDX GROUP, INC.; MIMEDX PROCESSING SERVICES, LLC
To: HAYFIN SERVICES LLP, AS COLLATERAL AGENT
Reel/Frame 053121/0833 →
RELEASE OF SECURITY INTEREST Recorded Jul 2, 2020
From: BLUE TORCH FINANCE LLC, AS COLLATERAL AGENT
To: MIMEDX GROUP, INC.; MIMEDX PROCESSING SERVICES, LLC
Reel/Frame 054075/0687 →
SECURITY INTEREST Recorded Jun 11, 2019
From: MIMEDX GROUP, INC.
To: BLUE TORCH FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 049426/0863 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jan 24, 2019
From: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
To: MIMEDX GROUP, INC.
Reel/Frame 048121/0835 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Oct 15, 2015
From: MIMEDX GROUP, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 036872/0498 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 5, 2013
From: KOOB, THOMAS J.; DENOZIERE, GUILHEM; BROWN, REBECCAH J.C.
To: MIMEDX GROUP, INC.
Reel/Frame 031147/0643 →
Continuity (1)
Related Publication 20140271728A1 · Sep 18, 2014
Cited By (3)
US 12,208,180 US 12,508,349 US 12,551,509